NICE final draft backs gene therapy for rare ‘bubble baby syndrome’ – The Pharma Letter
|
NICE final draft backs gene therapy for rare 'bubble baby syndrome'
The Pharma Letter The UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) today published final draft guidance recommending gene therapy Strimvelis, from UK pharma major GlaxoSmithKline (LSE: GSK), as an option for … NICE publishes final draft guidelines backing GSK's Strimvelis |
